NEW YORK, April 30, 2003 (PRIMEZONE) -- MEDIA ADVISORY -- FASLODEX(r) (fulvestrant) Injection, the most recent hormonal treatment to receive approval in the U.S. for metastatic breast cancer, is now part of the National Comprehensive Cancer Network's (NCCN) "Practice Guidelines in Oncology for Breast Cancer." FASLODEX is included in their updated treatment protocol for subsequent hormonal therapy for invasive breast cancer in postmenopausal women following prior antiestrogen treatment, as reported in the April 2003 edition of the Journal of the National Comprehensive Cancer Network (JNCCN). The NCCN "Practice Guidelines in Oncology for Breast Cancer" are widely considered by oncologists as the standard for clinical policy in care for women with breast cancer.
Facts About Breast Cancer
- Breast cancer is the most prevalent cancer among women and strikes one out of every nine American women
- 40,000 people will die this year from breast cancer
- Every thirteen minutes a woman will die from breast cancer and over 1 million women in the United States have died of this disease since 1970
- There are more than two million breast cancer survivors in America today
B-roll package Includes:
- Footage of Dr. Kent Osborne, patient lifestyle footage, product shot
Soundbites from:
Dr. Kent Osborne, Director of the Breast Center, Baylor College of Medicine, Houston, TX
Patients - Marcia Blanger, Sondra Aden, Dorla Hyatt